Seroatlas · Human Serome Atlas

SLC5A1

Sodium/glucose cotransporter 1

Also known as: D22S675, NAGT, SC5A1_HUMAN, SGLT1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P13866
Gene
SLC5A1
Ensembl
ENSG00000100170
Chromosome
22
Canonical length
664 aa
Protein class
Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Transporters
Subcellular location
Nuclear membrane,Golgi apparatus,Plasma membrane

OverviewNCBI Gene

This gene encodes a member of the sodium-dependent glucose transporter (SGLT) family. The encoded integral membrane protein is the primary mediator of dietary glucose and galactose uptake from the intestinal lumen. Mutations in this gene have been associated with glucose-galactose malabsorption. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jan 2012]

Canonical amino-acid sequenceUniProt

664 residues, UniProt reviewed canonical sequence.

>P13866|SLC5A1
     1  MDSSTWSPKT TAVTRPVETH ELIRNAADIS IIVIYFVVVM AVGLWAMFST NRGTVGGFFL
    61  AGRSMVWWPI GASLFASNIG SGHFVGLAGT GAASGIAIGG FEWNALVLVV VLGWLFVPIY
   121  IKAGVVTMPE YLRKRFGGQR IQVYLSLLSL LLYIFTKISA DIFSGAIFIN LALGLNLYLA
   181  IFLLLAITAL YTITGGLAAV IYTDTLQTVI MLVGSLILTG FAFHEVGGYD AFMEKYMKAI
   241  PTIVSDGNTT FQEKCYTPRA DSFHIFRDPL TGDLPWPGFI FGMSILTLWY WCTDQVIVQR
   301  CLSAKNMSHV KGGCILCGYL KLMPMFIMVM PGMISRILYT EKIACVVPSE CEKYCGTKVG
   361  CTNIAYPTLV VELMPNGLRG LMLSVMLASL MSSLTSIFNS ASTLFTMDIY AKVRKRASEK
   421  ELMIAGRLFI LVLIGISIAW VPIVQSAQSG QLFDYIQSIT SYLGPPIAAV FLLAIFWKRV
   481  NEPGAFWGLI LGLLIGISRM ITEFAYGTGS CMEPSNCPTI ICGVHYLYFA IILFAISFIT
   541  IVVISLLTKP IPDVHLYRLC WSLRNSKEER IDLDAEEENI QEGPKETIEI ETQVPEKKKG
   601  IFRRAYDLFC GLEQHGAPKM TEEEEKAMKM KMTDTSEKPL WRTVLNVNGI ILVTVAVFCH
   661  AYFA

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLC5A1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
14
Mean surface accessibility (rSASA)
0.23
Highest tissue expression
498 nTPM

Expression across tissuesHPA

Tissue

  • duodenum: 498 nTPM
  • small intestine: 285 nTPM
  • heart muscle: 71 nTPM
  • gallbladder: 25 nTPM
  • salivary gland: 19 nTPM
  • skin: 13 nTPM

Single-cell type

  • enterocytes: 1,404 nCPM
  • cholangiocytes: 173 nCPM
  • cardiomyocytes: 135 nCPM
  • late spermatids: 125 nCPM
  • enteric transient amplifying cells: 100 nCPM
  • esophageal apical cells: 82 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • hypothalamus: 2.4 nTPM
  • cerebellum: 1.7 nTPM
  • basal ganglia: 1.6 nTPM
  • cerebral cortex: 1.6 nTPM
  • medulla oblongata: 1.6 nTPM
  • pons: 1.6 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SLC5A1.

Disease | AllUniProt

Conditions SLC5A1 is implicated in, by any mechanism.

  • Congenital glucose/galactose malabsorption (GGM) MIM:606824

Disease | GeneticClinVar

45 pathogenic / likely-pathogenic of 548 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Congenital glucose-galactose malabsorption
  • SLC5A1-related disorder
  • Renal glycosuria
  • SLC5A1-related glucose/galactose malabsorption

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.77
gnomAD pLI
0
gnomAD missense Z
1.83
DepMap mean gene effect
-0.07
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLC5A1 as an antibody target. Whether an autoantibody or antibody against SLC5A1 could matter depends on whether native SLC5A1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLC5A1 is annotated at the cell surface, where native SLC5A1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SLC5A1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SLC5A1. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...